Breaks Categories: News

MondaySep 14, 2026 9:00 am

NetworkNewsBreaks – Telomir Pharmaceuticals (NASDAQ: TELO) Reports Telomir-Zn Growth Inhibition Across Human and Canine Osteosarcoma Models

Telomir Pharmaceuticals (NASDAQ: TELO) announced new research findings from The Ohio State University College of Veterinary Medicine demonstrating that Telomir-Zn produced growth inhibition across human and canine osteosarcoma cell-line models at similar low drug concentrations. The study, conducted under the direction of Shay Bracha, DVM, MS, DACVIM (Oncology), evaluated Telomir-Zn in one human and two canine osteosarcoma models, with the results supporting further translational investigation and a potential development pathway using naturally occurring canine osteosarcoma. Telomir is in discussions with The Ohio State University College of Veterinary Medicine and assessing next steps for a potential in vivo efficacy study in…

Continue Reading

FridaySep 11, 2026 3:10 pm

NetworkNewsBreaks – D-Wave Quantum Inc. (NASDAQ: QBTS) Finalizes Definitive Agreement with U.S. Department of Commerce for up to $100 Million to Accelerate U.S. Leadership in Quantum Computing

D-Wave Quantum Inc. (NASDAQ: QBTS) (“D-Wave” or the “Company”), the only dual-platform quantum computing company providing both annealing and gate-model systems, software and services, announced the execution of a definitive agreement with the U.S. Department of Commerce based on the previously announced Letter of Intent. D-Wave now has access to up to $100 million of U.S. CHIPS and Science Act funding. “We’re grateful to the U.S. government for this award to D-Wave and for the leadership it is demonstrating in advancing quantum innovation,” said Dr. Alan Baratz, CEO of D-Wave. “The Administration has made clear that U.S. quantum leadership will…

Continue Reading

FridaySep 11, 2026 2:10 pm

NetworkNewsBreaks – Greenland Mines Ltd. (NASDAQ: GRML) Completes Skaergaard Bulk-Sampling Program, Advances Sarfartoq Fieldwork 

Greenland Mines (NASDAQ: GRML) provided an update on its 2026 field programs at the Skaergaard palladium-platinum-gold project in East Greenland and Sarfartoq rare earth element project in West Greenland. At Skaergaard, the company completed its bulk-sample blasting program, collecting 104.8 tons of mineralized and host material from seven sites for large-scale and pilot-scale metallurgical test work at GTK Mintec in Finland, while also completing ground-penetrating radar surveys and advancing engineering, infrastructure, processing and waste-management studies. At Sarfartoq, Greenland Mines opened and fully manned its exploration camp following the Sept. 1 acquisition, completed a second year of environmental baseline fieldwork and launched geological and structural mapping focused on the ST1 resource zone and additional rare…

Continue Reading

FridaySep 11, 2026 12:10 pm

NetworkNewsBreaks – Stewards, Inc. (NASDAQ: SWRD) Receives Approval to Uplist to Nasdaq Capital Market

Stewards (NASDAQ: SWRD),a diversified financial platform spanning private credit, real assets and technology-enabled financial infrastructure, received approval from the Listing Qualifications Department of The Nasdaq Stock Market LLC to list its common stock on the Nasdaq Capital Market. The company said its shares will begin trading under the existing “SWRD” ticker through a direct uplisting, with no concurrent public offering or issuance of new shares. Stewards’ private credit platform has originated more than $153 million in cumulative direct and syndicated funding across more than 10,000 small businesses since 2020, while the company has also expanded into income-producing real assets and…

Continue Reading

FridaySep 11, 2026 11:30 am

NetworkNewsBreaks – Regentis Biomaterials Ltd. (NYSE American: RGNT) Reports First Half 2026 Results, Advances GelrinC(R) Pivotal Trial 

Regentis Biomaterials (NYSE American: RGNT), a regenerative medicine company focused on innovative tissue repair solutions, reported financial results for the six months ended June 30, 2026 and provided a corporate and clinical update. The company has recruited and treated 43 of 80 patients in its pivotal Phase III GelrinC(R) U.S. trial and now expects to complete enrollment around year-end. Regentis also expanded its U.S. and European clinical networks, advanced preparations for European commercialization and received regulatory approval in Europe for a new solvent-free manufacturing process that increases GelrinC(R) production yield by 400%. For the first half, Regentis reported a net loss of approximately $2.6 million, or $0.44 per share, compared…

Continue Reading

FridaySep 11, 2026 10:30 am

NetworkNewsBreaks – Vertical Data Inc. (OTCQB: VDTA) Enters Definitive Agreement to Acquire 4.5 MW Data Center Site in Sweden 

Vertical Data (OTCQB: VDTA), a vertically integrated AI infrastructure company providing GPU financing, AI hardware, sovereign cloud and edge data center solutions, entered into a definitive purchase agreement through its majority-owned Vertical Data Nordic AB to acquire an existing industrial data center site with 4.5 MW of power capacity in Sollefteå Municipality in Central Sweden. If the transaction proceeds, Vertical Data intends to continue pursuing an application for up to 100 MW of total power capacity to build out an AI data center facility. The company said the project is among several in an active conversion pipeline representing more than 250 MW of global data center opportunities.…

Continue Reading

FridaySep 11, 2026 10:22 am

NetworkNewsBreaks – Nanox Imaging Ltd. (NASDAQ: NNOX) Signs Nanox.ARC Distribution Agreement for Costa Rica

Nanox (NASDAQ: NNOX) announced a distribution agreement with Costa Rica-based medical equipment distributor SOLME RC, S.A. to market and support the Nanox.ARC, a multi-source digital tomosynthesis system designed to expand access to 3D medical imaging. SOLME will oversee marketing, distribution, installation, training and ongoing technical support in Costa Rica, where it is a registered supplier to the Caja Costarricense de Seguro Social (“CCSS”), the country principal purchaser and provider of hospital services. Commercialization will follow applicable regulatory registration, including an initial six-month proof-of-concept device registration period before full registration, and Costa Rica represents Nanox third Latin American market this year…

Continue Reading

FridaySep 11, 2026 9:20 am

NetworkNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) Featured in BioMedWire Editorial on Lucid-MS Phase 2 Trial

This article has been disseminated on behalf of Quantum BioPharma Ltd. and may include paid advertising. Quantum BioPharma (NASDAQ: QNTM) announced its placement in a BioMedWire editorial examining the potential of Lucid-MS to address limitations of existing multiple sclerosis (“MS”) treatments. The editorial highlights Quantum BioPharma’s U.S. Food and Drug Administration (“FDA”) clearance to launch a phase 2 trial of Lucid-MS, a patented, first-in-class candidate designed to protect and potentially rebuild the myelin sheath rather than suppress the immune system. According to the publication, the trial would mark the first time a drug based on this mechanism is tested in people…

Continue Reading

FridaySep 11, 2026 9:10 am

NetworkNewsBreaks – TransCode Therapeutics, Inc. (NASDAQ: RNAZ) Names John Tattory Interim CFO Following Tom Fitzgerald Retirement

TransCode Therapeutics (NASDAQ: RNAZ) a clinical stage company pioneering immuno-oncology and RNA for the treatment of high risk and advanced cancer, announced the retirement of Chief Financial Officer Tom Fitzgerald, who has served in the role since July 2018 and will resign as CFO and a director effective immediately while continuing to provide transition services. The company named John Tattory interim CFO, effective immediately. Tattory has more than 25 years of financial and operational management and leadership experience across pharmaceutical, medical device and biotechnology companies, including roles at Ernst & Young LLP, Bristol-Myers Squibb, Tyco International, Cerapedics and Windtree Therapeutics.…

Continue Reading

ThursdaySep 10, 2026 1:06 pm

NetworkNewsBreaks – AmpliTech Group, Inc. (NASDAQ: AMPG, AMPGZ) Receives $7.3 Million in Follow-On Orders for Asian 5G O-RAN Deployment 

AmpliTech Group (NASDAQ: AMPG, AMPGZ) received approximately $7.3 million in follow-on orders supporting deployments for an Asian mobile network operator (“MNO”) under its previously announced 5G O-RAN radio Letter of Intent (“LOI”) program. The orders follow deployment of AmpliTech O-RAN radios at end-customer 5G sites and represent renewed purchasing activity under the program. The company said the orders, together with recently received follow-on orders supporting its North American MNO program, restore momentum under the LOI program and support its efforts to convert its opportunity pipeline into shipments and revenue. To view the full press release, visit https://nnw.fm/IPa6Z About AmpliTech Group, Inc. AmpliTech Group, Inc. (Nasdaq: AMPG, AMPGZ)…

Continue Reading